Healthcare Industry News: electrocardiograph
News Release - August 5, 2008
NewCardio Names Ihor Gussak, M.D., Ph.D., FACC Chief Medical Officer
Former VP, Global Medical Affairs at eResearchTechnology, Inc., Adds Significant Experience with Major Pharmaceutical Companies, Academia, CROs, and Central ECG Core LaboratoriesSANTA CLARA, Calif.--(HSMN NewsFeed)--NewCardio, Inc. (OTCBB: NWCI ), a cardiac diagnostic and services company, announced today that Ihor Gussak, M.D., Ph.D., FACC, world-recognized expert in electrocardiology and cardiac safety, has joined the Company as its new Chief Medical Officer and Vice President, effective immediately.
Dr. Gussak joins NewCardio from Boehringer Ingelheim Pharmaceuticals, where he held a senior executive role for the past year. Previously, Dr. Gussak served 5 years as Vice President, Global Medical Affairs for eResearchTechnology, Inc., and held a key executive position with Aventis Pharmaceuticals Inc, employed by Mayo Clinic, and the ECG Core Lab at St. Louis University Health Sciences Center. He has participated in management of many clinical trials, consulted with many contract research organizations (CROs), and is credited with major contributions and publications in the field of cardiovascular medicine.
Dr. Gussak received his M.D. from Tartu University School of Medicine (Tartu, Estonia), and his PhD in Medical Sciences/Cardiac Electrophysiology (Acute Myocardial Ischemia in Clinic and Experiments) from the National Center for Surgical Treatment of Severe Cardiac Rhythm Disturbance and Cardiac Pacing (Kaunas, Lithuania). He received further training in the US at Mayo Clinic and the ECG Core Lab at St. Louis University Health Sciences Center. At present, he is Clinical Professor of Medicine at University of Medicine and Dentistry-Robert Wood Johnson Medical School, and Executive Editor, Journal of Electrocardiology, a position he has held since 2004.
Dr. Gussak’s primary scientific interests are in clinical electrocardiography and cardiac electrophysiology, including cardiac safety, cardiac arrhythmias, sudden cardiac death, Brugada syndrome, and Short QT syndrome. He has published several textbooks and numerous peer-reviewed articles on these and other subjects in clinical cardiology. His most recent published book, Electrical Diseases of the Heart and Sudden Cardiac Death: Genetics, Mechanisms, Treatment, Prevention (Ihor Gussak and Charles Antzelevitch, editors) was recently praised in the New England Journal of Medicine (359:103, July 3, 2008) as “a thoughtful and thorough review … a definitive text that will be useful to all who have an interest in cardiac arrhythmia.”
Dr. Gussak is a Fellow of the American College of Cardiology, and serves on the Clinical Cardiology Council of the American Heart Association. He is a member of the American Academy of Pharmaceutical Physicians, the International Cardiac Electrophysiology Society, the International Society for Holter and Noninvasive Electrocardiology, the Drug Information Association, and the International Scientific Committee on Arrhythmogenic Right Ventricular Dysplasia-Cardiomyopathy.
Branislav Vajdic, Ph.D., President and Chief Executive Officer, commented, “Dr. Gussak is a recognized leader around the world in the area of Clinical Trials and Cardiac Safety. We are exceptionally pleased to add him as a senior member of our management team and look forward to benefiting from his expertise and leadership. Dr. Gussak’s reputation within the industry, and relationships with leading pharmaceutical companies, as well as some of the top CROs in the world, and his efforts in clinical and academic research related to the electrical activity of the heart and ECG methodology should prove invaluable as we commercialize our QTinno™ product and further develop the 3D ECG platform technology which underlies this lead product. NewCardio’s capabilities to positively impact clinical trials, pharmaceutical research, and both the acute and long-term care of patients with heart conditions should be enhanced by Dr. Gussak’s contributions.”
Dr. Gussak added, “I believe NewCardio’s 3D ECG platform technology possesses unique promise areas as a diagnostic tool in a broad range of cardiovascular diseases. For more than 100 years, the ECG has been the standard tool for evaluating disorders of cardiac electrical activity, but until now the technology has not been significantly improved. NewCardio’s 3D ECG technology offers the potential to provide more diagnostic information, more rapid and reproducible ECG readings, and more accurate and cost-effective clinical trials. I am truly excited to be part of the development of this technology.”
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio’s development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio’s three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K/A (No. 1) for the year ended December 31, 2007 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
Source: NewCardio
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
